Merus Labs International Inc. Form 6-K August 11, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2014

Commission File No. 00-30082

MERUS LABS INTERNATIONAL INC.

(Translation of registrant's name into English)

100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F **Form 20-F [X]** Form 40-F []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) []

SUBMITTED HEREWITH

Exhibits	
<u>99.1</u>	Acquisition Agreement dated July 4, 2014
<u>99.2</u>	News Release dated July 17, 2014
<u>99.3</u>	News Release dated August 7, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 8, 2014

MERUS LABS INTERNATIONAL INC.

<u>/s/ Andrew Patient</u> Andrew Patient Chief Financial Officer